• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

替格瑞洛引起的晕厥/缓慢性心律失常。

Ticagrelor-Induced Syncope/Bradyarrhythmia.

作者信息

Kotaru VeeraPavan, Kalavakunta Jagadeesh K

机构信息

Cardiology, Ascension Borgess Hospital, Kalamazoo, USA.

出版信息

Cureus. 2021 Jan 23;13(1):e12874. doi: 10.7759/cureus.12874.

DOI:10.7759/cureus.12874
PMID:33633903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7899257/
Abstract

Ticagrelor (BRILINTA®) is a very commonly used oral antiplatelet agent in acute coronary syndrome and after percutaneous coronary intervention (PCI). It is a reversible, direct inhibitor of the adenosine diphosphate (ADP) P2Y12 receptor. Most of the patients tolerate the drug well but it is known to cause brady arrhythmias and ventricular pauses, the exact mechanism of which is unclear. We present a case of acute coronary syndrome/unstable angina in a 58-year-old Caucasian gentleman requiring cardiac catheterization and PCI with drug eluting stent deployment and syncope following Ticagrelor loading from long ventricular pauses.

摘要

替格瑞洛（倍林达®）是急性冠状动脉综合征及经皮冠状动脉介入治疗（PCI）后常用的口服抗血小板药物。它是一种可逆的二磷酸腺苷（ADP）P2Y12受体直接抑制剂。大多数患者对该药耐受性良好，但已知其会引起缓慢性心律失常和心室停搏，确切机制尚不清楚。我们报告一例58岁白种男性急性冠状动脉综合征/不稳定型心绞痛患者，该患者需要进行心脏导管插入术及植入药物洗脱支架的PCI治疗，在替格瑞洛负荷给药后因长时间心室停搏出现晕厥。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7754/7899257/a2d7ab6f3802/cureus-0013-00000012874-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7754/7899257/3f20c805c9ad/cureus-0013-00000012874-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7754/7899257/3bdb8e806b77/cureus-0013-00000012874-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7754/7899257/a2d7ab6f3802/cureus-0013-00000012874-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7754/7899257/3f20c805c9ad/cureus-0013-00000012874-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7754/7899257/3bdb8e806b77/cureus-0013-00000012874-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7754/7899257/a2d7ab6f3802/cureus-0013-00000012874-i03.jpg

相似文献

1
Ticagrelor-Induced Syncope/Bradyarrhythmia.替格瑞洛引起的晕厥/缓慢性心律失常。
Cureus. 2021 Jan 23;13(1):e12874. doi: 10.7759/cureus.12874.
2
Ticagrelor-associated ventricular pauses: a case report and literature review.替格瑞洛相关的心室停搏：一例病例报告及文献综述
Eur Heart J Case Rep. 2018 Dec 28;3(1):yty156. doi: 10.1093/ehjcr/yty156. eCollection 2019 Mar.
3
A rare but serious complication of ticagrelor therapy: a case report.替格瑞洛治疗的一种罕见但严重的并发症：一例病例报告。
Eur Heart J Case Rep. 2020 Aug 20;4(5):1-5. doi: 10.1093/ehjcr/ytaa156. eCollection 2020 Oct.
4
Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.2008-2016 年经皮冠状动脉介入治疗后抗血小板药物初治患者中血小板二磷酸腺苷 P2Y12 受体抑制剂的使用和依从性趋势。
JAMA Intern Med. 2018 Jul 1;178(7):943-950. doi: 10.1001/jamainternmed.2018.0783.
5
Heart Block Caused by Ticagrelor Use in a Patient Who Underwent Adenosine Diastolic Fractional Reserve Assessment: A Case Report.替格瑞洛用于接受腺苷舒张期分数储备评估患者导致心脏传导阻滞：一例报告
J Med Cases. 2021 Dec;12(12):499-502. doi: 10.14740/jmc3815. Epub 2021 Dec 2.
6
Ticagrelor: a review of its use in adults with acute coronary syndromes.替格瑞洛：用于成人急性冠脉综合征的综述
Am J Cardiovasc Drugs. 2015 Feb;15(1):51-68. doi: 10.1007/s40256-015-0108-5.
7
Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.急性冠状动脉综合征经皮冠状动脉介入治疗患者负荷剂量替格瑞洛后用 VASP 检测血小板反应性。
Thromb Res. 2013 Jul;132(1):e15-8. doi: 10.1016/j.thromres.2013.04.030. Epub 2013 May 30.
8
Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.接受经皮冠状动脉血运重建的急性冠状动脉综合征患者中P2Y12抑制剂使用及转换情况的评估
Int J Cardiol. 2016 Nov 15;223:854-859. doi: 10.1016/j.ijcard.2016.08.144. Epub 2016 Aug 8.
9
Successful Reversal of Bradycardia and Dyspnea With Aminophylline After Ticagrelor Load.替格瑞洛负荷剂量给药后，氨茶碱成功逆转心动过缓和呼吸困难。
J Pharm Pract. 2018 Feb;31(1):112-114. doi: 10.1177/0897190016680978. Epub 2016 Dec 5.
10
Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.接受维持剂量P2Y12-ADP受体拮抗剂治疗的患者在接受择期经皮冠状动脉介入治疗时的血小板反应性。
Int J Cardiol. 2016 Aug 1;216:190-3. doi: 10.1016/j.ijcard.2016.04.165. Epub 2016 May 1.

引用本文的文献

1
A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.替格瑞洛的美国食品药品监督管理局不良事件报告系统（FAERS）事件的不成比例性分析。
Front Pharmacol. 2024 Apr 9;15:1251961. doi: 10.3389/fphar.2024.1251961. eCollection 2024.

本文引用的文献

1
Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.替格瑞洛：药代动力学、药效学、临床疗效及安全性。
Pharmacotherapy. 2014 Oct;34(10):1077-90. doi: 10.1002/phar.1477. Epub 2014 Aug 28.
2
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.PLATO（血小板抑制和患者结局）试验中接受替格瑞洛或氯吡格雷治疗的急性冠脉综合征患者的缓心律失常和临床缓心律失常事件的发生率：连续心电图评估子研究结果。
J Am Coll Cardiol. 2011 May 10;57(19):1908-16. doi: 10.1016/j.jacc.2010.11.056.
3
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
替格瑞洛与氯吡格雷用于急性冠脉综合征患者的比较
N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.